Head & Neck/Thyroid Cancers
Conference Coverage
ESMO 2018: First look at immunotherapy as first-line treatment for HNSCC
Results of KEYNOTE-048, a study of pembrolizumab for first-line treatment of recurrent or metastatic HNSCC, will be presented at ESMO 2018.
From the Journals
Epacadostat plus pembrolizumab shows promise in advanced solid tumors
Investigational drug epacadostat plus pembrolizumab demonstrated promising antitumor activity and safety in patients with advanced solid tumors....
From the Journals
First combo trial of mTOR/BRAF inhibition shows potential
A combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus and the BRAF inhibitor vemurafenib appears safe for patients with...
Case Reports
Extramedullary plasmacytoma of the thyroid, refractory to radiation therapy and treated with bortezomib
Case Reports
Salivary ductal adenocarcinoma with complete response to androgen blockade
New Therapies
Meeting the potential of immunotherapy: new targets provide rational combinations
From the Journals
HPV positivity associated with good esophageal adenocarcinoma outcomes
Patients with esophageal adenocarcinoma who were HPV positive had significantly better disease-free and overall survival.
Case Reports
Effective management of severe radiation dermatitis after head and neck radiotherapy
Original Report
The impact of inpatient rehabilitation on outcomes for patients with cancer
Conference Coverage
H&N cancer may be undertreated in women
CHICAGO – Female patients with H&N cancer had almost twice the ratio of cancer deaths to noncancer deaths.
Conference Coverage
Head and neck cancers: Women less commonly receive intensive chemo
CHICAGO - Senior study author Dr. Jed A. Katzel discusses ongoing research to understand the reasons behind the apparent disparities.